Carfilzomib experience in relapsed/refractory multiple myeloma: a single-center experience

Basit Öğe Kaydı
dc.contributor.authorUysal, Ayse
dc.contributor.authorAkad Soyer, Nur
dc.contributor.authorOzkan, Melda
dc.contributor.authorSahin, Fahri
dc.contributor.authorVural, Filiz
dc.contributor.authorTobu, Mahmut
dc.contributor.authorTombuloglu, Murat
dc.contributor.authorSaydam, Guray
dc.date.accessioned2019-07-08T07:31:59Z
dc.date.available2019-07-08T07:31:59Z
dc.date.issued2018
dc.departmentİnönü Üniversitesien_US
dc.description.abstractBackground/aim: Carfilzomib (CFZ) is a new-generation proteasome inhibitor with significant activity in relapsed or refractory multiple myeloma (R/R-MM). We have retrospectively evaluated R/R-MM patients who were treated with CFZ plus dexamethasone. Materials and methods: Twenty-one R/R-MM patients who were treated with CFZ plus dexamethasone between October 2013 and January 2016 were screened. The patients were followed until March 2016 after CFZ treatment. Results: Ten (47.6%) of the patients were female and 11 (52.4%) of them were male. The median age was 62 (47-76) years. The median number of prior treatment lines was 3 (2-7). The median number of administered cycles of treatment for CFZ was 4 (1-10). The median overall response rate was 26.3%. The most common hematological adverse events were anemia and thrombocytopenia (38%). The most common nonhematological adverse event was fatigue (71.4%). One patient died because of a cerebrovascular event and 1 patient died because of pneumonia during the treatment period. The median duration of response rate and time to next therapy were 8 (7-9) and 3 (2-16) months, respectively. The median overall survival was 8 (0.5-33) months. Conclusion: Despite the small number of patients, our results suggest that CFZ provides acceptable responses in heavily pretreated R/R-MM patients.en_US
dc.identifier.citationUysal, A. Akad Soyer, N. Ozkan, M. Sahin, F . Vural, F. Tobu, M. Tombuloglu, M. Saydam, G. (2018). Carfilzomib experience in relapsed/refractory multiple myeloma: a single-center experience. Cilt:48. Sayı:1. 80-83 ss.en_US
dc.identifier.doi10.3906/sag-1611-97en_US
dc.identifier.endpage83en_US
dc.identifier.issue1en_US
dc.identifier.startpage80en_US
dc.identifier.urihttps://hdl.handle.net/11616/12381
dc.identifier.volume48en_US
dc.language.isoenen_US
dc.publisherTubıtak scıentıfıc & technıcal research councıl turkey, ataturk bulvarı no 221, kavaklıdere, ankara, 00000, turkeyen_US
dc.relation.ispartofTurkısh journal of medıcal scıencesen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectAgent carfılzomıben_US
dc.subjectworkıng groupen_US
dc.subjectbortezomıben_US
dc.subjecttherapyen_US
dc.subjectmultıcenteren_US
dc.titleCarfilzomib experience in relapsed/refractory multiple myeloma: a single-center experienceen_US
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
makale dosyası.pdf
Boyut:
82.75 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Makale dosyası
İndir
Lisans paketi
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
license.txt
Boyut:
1.71 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

Tıp Fakültesi, İç Hastalıkları Anabilim Dalı Koleksiyonu